A PHASE I TRIAL FOR THE USE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) IN THE TREATMENT OF BCG-REFRACTORY NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER

被引：4
|
作者：
DeCastro, Guarionex
Sui, Wilson
Pak, Jamie
Abate-Shen, Cory
Lee, Shing
Anderson, Christopher
Holder, Dara
McKiernan, James
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 04期
关键词：
D O I：
10.1016/j.juro.2017.02.498
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP15-13
引用
收藏
页码：E175 / E176
页数：2
相关论文
共 50 条
  • [11] Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
    Zahoor, Haris
    Mir, Maria C.
    Barata, Pedro C.
    Stephenson, Andrew J.
    Campbell, Steven C.
    Fergany, Amr
    Dreicer, Robert
    Garcia, Jorge A.
    [J]. INVESTIGATIONAL NEW DRUGS, 2019, 37 (06) : 1231 - 1238
  • [12] Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer
    Haris Zahoor
    Maria C. Mir
    Pedro C. Barata
    Andrew J. Stephenson
    Steven C. Campbell
    Amr Fergany
    Robert Dreicer
    Jorge A. Garcia
    [J]. Investigational New Drugs, 2019, 37 : 1231 - 1238
  • [13] Intravesical Admistration of Gemcitabine for the Treatment of non-muscle invasive Bladder Cancer
    Spek, Annabel
    [J]. UROLOGIE, 2022, 61 (06): : 653 - 656
  • [14] PHASE I/II TRIAL OF INTRAVESICAL NANOPARTICLE ALBUMIN- BOUND PACLITAXEL FOR THE TREATMENT OF BCG REFRACTORY NON-MUSCLE INVASIVE TRANSITIONAL CELL CARCINOMA
    Holder, Dara
    Castaneda, Crystal
    Ahn, Jennifer
    Badalato, Gina
    Barlow, LaMont
    Mann, Mark
    RoyChoudhury, Arindam
    Benson, Mitchell
    Mckiernan, James
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E698 - E698
  • [15] Sunitinib in BCG-refractory non-muscle-invasive transitional cell carcinoma of the bladder
    Garcia, J. A.
    Stephenson, A. J.
    Ireland, J.
    Finke, J.
    Elson, P.
    Schaaf, L.
    Gong, M. C.
    Campbell, S.
    Dreicer, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [16] Which maintenance treatment with intravesical BCG in non-muscle invasive bladder tumors?
    Galliot, Ismael
    Pfister, Christian
    [J]. PROGRES EN UROLOGIE, 2011, 21 (01): : F16 - F21
  • [17] Phase II trial of intravesical gemcitabine in BCG refractory transitional cell carcinoma of the bladder
    Dalbagni, G
    Mazumdar, M
    Russo, P
    Sheinfeld, J
    Donat, SM
    Bochner, BH
    Herr, HW
    Sogani, P
    Ginty, J
    Bajorin, DF
    [J]. JOURNAL OF UROLOGY, 2004, 171 (04): : 72 - 72
  • [18] A phase I study of intravesical camrelizumab for BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC)
    Wang, Y.
    Xu, P. H.
    Bian, X. J.
    Lu, X. L.
    Wang, Z.
    Wang, X.
    Yao, X. D.
    Shen, Y. J.
    Ye, D. Y.
    [J]. EUROPEAN UROLOGY, 2022, 81 : S251 - S251
  • [19] The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience
    Barlow, LaMont J.
    McKiernan, James M.
    Benson, Mitchell C.
    [J]. WORLD JOURNAL OF UROLOGY, 2009, 27 (03) : 331 - 335
  • [20] INTRAVESICAL BACILLUS CALMETTE - GUERIN: PATTERNS OF USE AND OUTCOMES FOR NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER
    Huang, Dora
    Khan, Munad
    Azer, Sarah
    Sengupta, Shomik
    Lawrentschuk, Nathan
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 48 - 48
12345